Patents by Inventor Philippe Marcel Nuhant
Philippe Marcel Nuhant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12331057Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.Type: GrantFiled: October 16, 2023Date of Patent: June 17, 2025Assignee: Vertex Pharmaceuticals IncorporatedInventors: Upul Keerthi Bandarage, Cavan McKeon Bligh, Diane Boucher, Michael John Boyd, Michael Aaron Brodney, Michael Philip Clark, Veronique Damagnez, Lev Tyler Dewey Fanning, Robert Francis Fimognari, Gabrielle Simone Fleming, Kevin James Gagnon, Pedro Manuel Garcia Barrantes, Robert Daniel Giacometti, Simon Giroux, Ronald Lee Grey, Jr., Samantha Guido, Amy Beth Hall, Sarah Carol Hood, Dennis James Hurley, Mac Arthur Johnson, Jr., Peter Jones, Sarathy Kesavan, Mei-Hsiu Lai, Siying Liu, Adam Looker, Brad Maxwell, John Patrick Maxwell, Ales Medek, Philippe Marcel Nuhant, Kirk Alan Overhoff, Setu Roday, Stefanie Roeper, Steven M. Ronkin, Rupa Sawant, Yi Shi, Muna Shrestha, Marisa Sposato, Kathy Stavropoulos, Rebecca Jane Swett, Timothy Lewis Tapley, Qing Tang, Stephen Thomson, Jinwang Xu, Mariam Zaky, Kevin Michael Cottrell
-
Patent number: 12312344Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.Type: GrantFiled: May 3, 2023Date of Patent: May 27, 2025Assignee: Pfizer Inc.Inventors: Brian Stephen Gerstenberger, Andrew Christopher Flick, Daniel Wei-Shung Kung, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, Jr., Daniel Copley Schmitt, Mark Edward Schnute, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
-
Publication number: 20240368144Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.Type: ApplicationFiled: May 3, 2023Publication date: November 7, 2024Applicant: Pfizer Inc.Inventors: Brian Stephen Gerstenberger, Andrew Christopher Flick, Daniel Wei-Shung Kung, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, JR., Daniel Copley Schmitt, Mark Edward Schnute, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
-
Publication number: 20240336614Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.Type: ApplicationFiled: October 16, 2023Publication date: October 10, 2024Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Diane BOUCHER, Michael John BOYD, Michael Aaron BRODNEY, Michael Philip CLARK, Veronique DAMAGNEZ, Lev Tyler Dewey FANNING, Robert Francis FIMOGNARI, Gabrielle Simone FLEMING, Kevin James GAGNON, Pedro Manuel GARCIA BARRANTES, Robert Daniel GIACOMETTI, Simon GIROUX, Ronald Lee GREY, JR., Samantha GUIDO, Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Mac Arthur JOHNSON, JR., Peter Jones, Sarathy KESAVAN, Mei-Hsiu LAI, Siying LIU, Adam LOOKER, Brad MAXWELL, John Patrick MAXWELL, Ales MEDEK, Philippe Marcel NUHANT, Kirk Alan OVERHOFF, Setu RODAY, Stefanie ROEPER, Steven M. RONKIN, Rupa SAWANT, Yi SHI, Muna SHRESTHA, Marisa SPOSATO, Kathy STAVROPOULOS, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Qing TANG, Stephen THOMSON, Jinwang XU, Mariam ZAKY, Kevin Michael COTTRELL
-
Patent number: 11884672Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.Type: GrantFiled: May 13, 2020Date of Patent: January 30, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Upul Keerthi Bandarage, Cavan McKeon Bligh, Diane Boucher, Michael John Boyd, Michael Aaron Brodney, Michael Philip Clark, Veronique Damagnez, Lev Tyler Dewey Fanning, Robert Francis Fimognari, Gabrielle Simone Fleming, Kevin James Gagnon, Pedro Manuel Garcia Barrantes, Robert Daniel Giacometti, Simon Giroux, Ronald Lee Grey, Jr., Samantha Guido, Amy Beth Hall, Sarah Carol Hood, Dennis James Hurley, Mac Arthur Johnson, Jr., Peter Jones, Sarathy Kesavan, Mei-Hsiu Lai, Siying Liu, Adam Looker, Brad Maxwell, John Patrick Maxwell, Ales Medek, Philippe Marcel Nuhant, Kirk Alan Overhoff, Setu Roday, Stefanie Roeper, Steven M. Ronkin, Rupa Sawant, Yi Shi, Muna Shrestha, Marisa Sposato, Kathy Stavropoulos, Rebecca Jane Swett, Timothy Lewis Tapley, Qing Tang, Stephen Thomson, Jinwang Xu, Mariam Zaky, Kevin Michael Cottrell
-
Publication number: 20230339915Abstract: Novel compounds, compositions, and methods of using and preparing the same, which maybe useful for treating alpha-1 antitrypsin deficiency (AATD).Type: ApplicationFiled: April 2, 2021Publication date: October 26, 2023Inventors: Simon GIROUX, Michael Philip CLARK, Qing TANG, Philippe Marcel NUHANT, Peter JONES, David MESSERSMITH, Upul Keerthi BANDARAGE, Kevin Michael COTTRELL, Michael Aaron BRODNEY, Gabrielle Simone FLEMING, Jian WANG, Jinwang XU, Kevin Brett DANIEL, Michael John BOYD, Mark A. MORRIS, Nathan D. WAAL, Philip Noel COLLIER, Sarathy KESAVAN, Steven M. RONKIN, Hongbo DENG, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ
-
Publication number: 20230265080Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).Type: ApplicationFiled: February 9, 2023Publication date: August 24, 2023Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Michael John BOYD, Diane M. BOUCHER, Michael Aaron BRODNEY, Veronique DAMAGNEZ, Lev Tyler DEWEY FANNING, Mary Elizabeth ECCLES, Robert Francis FIMOGNARI, JR., Kevin James GAGNON, Pedro M. GARCIA BARRANTES, Simon GIROUX, Ronald Lee GREY, JR., Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Joshua Kennedy HUSSEY, Mac Arthur JOHNSON, JR., Peter JONES, Sarathy KESAVAN, Adam LOOKER, Brad D. MAXWELL, John Patrick MAXWELL, Ales MEDEK, Mettachit NAVAMAL, Philippe Marcel NUHANT, Setu RODAY, Stefanie ROEPER, Rupa SAWANT, Yi SHI, Rebecca Jane SWETT, Qing TANG, Timothy Lewis TAPLEY, Stephen A. THOMSON, Michael WALDO, Jinwang XU, Kevin Michael COTTRELL
-
Patent number: 11708360Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.Type: GrantFiled: March 5, 2021Date of Patent: July 25, 2023Assignee: Pfizer Inc.Inventors: Brian Stephen Gerstenberger, Andrew Christopher Flick, Daniel Wei-Shung Kung, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, Jr., Daniel Copley Schmitt, Mark Edward Schnute, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
-
Publication number: 20230159502Abstract: Indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).Type: ApplicationFiled: April 2, 2021Publication date: May 25, 2023Inventors: Simon GIROUX, Michael Philip CLARK, Michael Aaron BRODNEY, Philippe Marcel NUHANT, Emily Elizabeth ALLEN, Robert Francis FIMOGNARI, Jr., Mariam ZAKY, Michael John BOYD, David D. DEININGER, Hu ZHANG, Hongbo DENG, Philip Noel COLLIER, Brad MAXWELL, Nathan D. WAAL, Steven M. RONKIN, Jian WANG, Qing TANG, Gabrielle Simone FLEMING, Peter JONES, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ, Kevin Michael COTTRELL, Upul Keerthi BANDARAGE
-
Publication number: 20230159521Abstract: 1H-pyrazolo[4,3-g]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).Type: ApplicationFiled: April 2, 2021Publication date: May 25, 2023Inventors: Simon GIROUX, Philippe Marcel NUHANT, Upul Keerthi BANDARAGE, Pedro Manuel GARCIA BARRANTES, Yusheng LIAO, Zachary GALE-DAY, Wenxin GU, Alexander S. KARNS, Hu ZHANG, Emily Elizabeth ALLEN, Jinwang XU, Michael Paul DENINNO, Qing TANG, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ, Kevin Michael COTTRELL
-
Publication number: 20230159580Abstract: Pyrrolo[2,3-f]indazole and 2,4,5,10-tetrazatricyclo[7.3.0.Type: ApplicationFiled: April 2, 2021Publication date: May 25, 2023Inventors: Simon GIROUX, Michael John BOYD, Robert Francis FIMOGNARI, Jr., Mariam ZAKY, Ronald Lee GREY, Jr., Jinwang XU, Sarathy KESAVAN, Philippe Marcel NUHANT, Pedro Manuel GARCIA BARRANTES, Peter JONES, Michael Aaron BRODNEY, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ, Kevin Michael COTTRELL
-
Patent number: 11623924Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).Type: GrantFiled: October 4, 2019Date of Patent: April 11, 2023Assignee: Vertex Pharmaceuticals IncorporatedInventors: Upul Keerthi Bandarage, Cavan McKeon Bligh, Michael John Boyd, Diane M. Boucher, Michael Aaron Brodney, Veronique Damagnez, Lev Tyler Dewey Fanning, Mary Elizabeth Eccles, Robert Francis Fimognari, Jr., Kevin James Gagnon, Pedro M. Garcia Barrantes, Simon Giroux, Ronald Lee Grey, Jr., Amy Beth Hall, Sarah Carol Hood, Dennis James Hurley, Joshua Kennedy Hussey, Mac Arthur Johnson, Jr., Peter Jones, Sarathy Kesavan, Adam Looker, Brad D. Maxwell, John Patrick Maxwell, Ales Medek, Mettachit Navamal, Philippe Marcel Nuhant, Setu Roday, Stefanie Roeper, Rupa Sawant, Yi Shi, Rebecca Jane Swett, Qing Tang, Timothy Lewis Tapley, Stephen A. Thomson, Michael Waldo, Jinwang Xu, Kevin Michael Cottrell
-
Publication number: 20210206757Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.Type: ApplicationFiled: March 5, 2021Publication date: July 8, 2021Applicant: Pfizer Inc.Inventors: Brian Stephen Gerstenberger, Andrew Christopher Flick, Daniel Wei-Shung Kung, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, JR., Daniel Copley Schmitt, Mark Edward Schnute, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
-
Publication number: 20210179587Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).Type: ApplicationFiled: October 4, 2019Publication date: June 17, 2021Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Michael John BOYD, Diane M. BOUCHER, Michael Aaron BRODNEY, Veronique DAMAGNEZ, Lev Tyler DEWEY FANNING, Mary Elizabeth ECCLES, Robert Francis FIMOGNARI, JR., Kevin James GAGNON, Pedro M. GARCIA BARRANTES, Simon GIROUX, Ronald Lee GREY, JR., Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Joshua Kennedy HUSSEY, Mac Arthur JOHNSON, JR., Peter JONES, Sarathy KESAVAN, Adam LOOKER, Brad D. MAXWELL, John Patrick MAXWELL, Ales MEDEK, Mettachit NAVAMAL, Philippe Marcel NUHANT, Setu RODAY, Stefanie ROEPER, Rupa SAWANT, Yi SHI, Rebecca Jane SWETT, Qing TANG, Timothy Lewis TAPLEY, Stephen A. THOMSON, Michael WALDO, Jinwang XU
-
Patent number: 10975065Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.Type: GrantFiled: September 20, 2019Date of Patent: April 13, 2021Assignee: Pfizer Inc.Inventors: Brian Stephen Gerstenberger, Andrew Christopher Flick, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, Jr., Mark Edward Schnute, Daniel Wei-Shung Kung, Daniel Copley Schmitt, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
-
Publication number: 20200361939Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.Type: ApplicationFiled: May 13, 2020Publication date: November 19, 2020Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Diane BOUCHER, Michael John BOYD, Michael Aaron BRODNEY, Michael Philip CLARK, Veronique DAMAGNEZ, Lev Tyler Dewey FANNING, Robert Francis FIMOGNARI, Gabrielle Simone FLEMING, Kevin James GAGNON, Pedro Manuel GARCIA BARRANTES, Robert Daniel GIACOMETTI, Simon GIROUX, Ronald Lee GREY, Jr., Samantha GUIDO, Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., Peter Jones, Sarathy KESAVAN, Mei-Hsiu LAI, Siying LIU, Adam LOOKER, Brad MAXWELL, John Patrick MAXWELL, Ales MEDEK, Philippe Marcel NUHANT, Kirk Alan OVERHOFF, Setu RODAY, Stefanie ROEPER, Steven M. RONKIN, Rupa SAWANT, Yi SHI, Muna SHRESTHA, Marisa SPOSATO, Kathy STAVROPOULOS, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Qing TANG, Stephen THOMSON, Jinwang XU, Mariam ZAKY
-
Publication number: 20200095239Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.Type: ApplicationFiled: September 20, 2019Publication date: March 26, 2020Applicant: Pfizer Inc.Inventors: Brian Stephen Gerstenberger, Andrew Christopher Flick, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, JR., Mark Edward Schnute, Daniel Wei-Shung Kung, Daniel Copley Schmitt, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
